Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The handbook's GFR-based 2.5 mg twice-daily AF rows differ from the U.S. label's combined age, weight and serum-creatinine criteria. Dialysis evidence is limited. No combined algorithm has been generated.
Check source scope before reading a dose
Eliquis - labeled renal guidance
Product / population
Apixaban (Eliquis), adult oral tablets, nonvalvular AF
Renal method
Serum creatinine (mg/dL), age (years) and weight (kg)
All record notes are retained here, including notes about sources not selected in this review.
Eliquis - product and source limitations
The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data.
What to reconcile: Apply only to the stated formulation, indication and renal population.
For adult nonvalvular AF, use 2.5 mg twice daily when at least two are present: age 80 years or older, body weight 60 kg or less, or serum creatinine at least 1.5 mg/dL. The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data.
RDM74-eliquis-official-1 · Source locator: Renal guidance: 2.1 and 8.6
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
